The role of biological therapy in metastatic colorectal cancer after first-line treatment: a meta-analysis of randomised trials

por Segelov, E, Chan, D, Shapiro, J, Price, T J, Karapetis, C S, Tebbutt, N C, Pavlakis, N
Publicado 2014

Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer

por Rowland, A, Dias, M M, Wiese, M D, Kichenadasse, G, McKinnon, R A, Karapetis, C S, Sorich, M J
Publicado 2015

Do metastatic colorectal cancer patients who present with late relapse after curative surgery have a better survival?

por Broadbridge, V T, Karapetis, C S, Beeke, C, Woodman, R J, Padbury, R, Maddern, G, Kim, S W, Roder, D, Hakendorf, P, Price, T J
Publicado 2013

Gemcitabine and carboplatin in carcinoma of unknown primary site: a phase 2 Adelaide Cancer Trials and Education Collaborative study

por Pittman, K B, Olver, I N, Koczwara, B, Kotasek, D, Patterson, W K, Keefe, D M, Karapetis, C S, Parnis, F X, Moldovan, S, Yeend, S J, Price, T J
Publicado 2006

Epiregulin gene expression as a biomarker of benefit from cetuximab in the treatment of advanced colorectal cancer

por Jonker, D J, Karapetis, C S, Harbison, C, O'Callaghan, C J, Tu, D, Simes, R J, Malone, D P, Langer, C, Tebbutt, N, Price, T J, Shapiro, J, Siu, L L, Wong, R P W, Bjarnason, G, Moore, M J, Zalcberg, J R, Khambata-Ford, S
Publicado 2014